



# Our Pipeline

Information is current as of 3/1/2022, updates are made on a quarterly basis

DISCOVERY

PRE-CLINICAL


CLINICAL

COMMERCIAL


## RNA-TARGETED THERAPIES PMO



## RNA-TARGETED THERAPIES PPMO



## GENE THERAPY



## GENE EDITING



\*Candidate received accelerated approval in the U.S., confirmatory studies required

\*\*Other exon targets in development: 43, 44, 50, and 55

\*\*\*Roche has the exclusive right to launch and commercialize SRP-9001 outside the United States

\*\*\*\*Gene therapy and PPMO

Duchenne - Duchenne muscular dystrophy  
 EDMD - Emery Dreifuss muscular dystrophy  
 LGMD - Limb-girdle muscular dystrophy  
 CMT - Charcot-Marie-Tooth disease  
 CNS - Central nervous system  
 CM - Cardiomyopathy  
 MS - Multiple Sclerosis

DISCOVERY

PRE-CLINICAL

CLINICAL

COMMERCIAL

## RNA-TARGETED THERAPIES PMO

SRP-4051*	Duchenne
SRP-4053*	Duchenne
SRP-4045*	Duchenne
Exon 52	Duchenne
Other Exon Targets**	Duchenne

## RNA-TARGETED THERAPIES PPMO

SRP-5051	Duchenne
SRP-5053	Duchenne
SRP-5045	Duchenne
SRP-5052	Duchenne
SRP-5044	Duchenne
SRP-5050	Duchenne

## GENE THERAPY

SRP-9001 Micro-dystrophin***	Duchenne
GALGT2 <i>Nationwide Children's</i>	Duchenne
GNT 0004 <i>Genethon</i>	Duchenne
SRP-9003 (LGMD2E $\beta$ -sarcoglycan)	LGMD
SRP-9004 (LGMD2D $\alpha$ -sarcoglycan)	LGMD
SRP-9005 (LGMD2C $\gamma$ -sarcoglycan)	LGMD
SRP-6004 (LGMD2B Dysferlin)	LGMD
SRP-9006 (LGMD2L Anoctamin 5)	LGMD
Calpain 3 (LGMD2A) <i>Nationwide Children's</i>	LGMD
Neurotrophin 3 (CMT 1A) <i>Nationwide Children's</i>	CMT
LYS-SAF 302 (MPS TYPE IIIA) <i>Lysogene</i>	MPS
Cardiomyopathy <i>University of Florida</i>	CM
CNS-1 <i>Lacerta</i>	CNS
Pompe Disease <i>Lacerta</i>	Pompe
Niemann-Pick Type C <i>StrideBio</i>	Niemann-Pick
Rett Syndrome 2 <i>StrideBio</i>	Rett
Dravet Syndrome <i>StrideBio</i>	Dravet
Angelman Syndrome <i>StrideBio</i>	Angelman
Four Muscle/CNS Targets <i>StrideBio</i>	Muscle/CNS
Emery-Dreifuss Muscular Dystrophy Type 1 <i>Columbia University</i>	EDMD
Multiple Sclerosis <i>University of Florida</i>	MS
Rett Syndrome 1 <i>University of Massachusetts</i>	Rett
Duchenne <i>Institute of Myology****</i>	Duchenne

## GENE EDITING

CRISPR/CAS9 <i>Duke University</i>	Duchenne
Duchenne <i>Harvard University</i>	Duchenne

\*Candidate received accelerated approval in the U.S., confirmatory studies required.

SRP-4051, SRP-4053 and SRP-4045 are not approved in Europe.

\*\*Other exon targets in development: 43, 44, 50, and 55


\*\*\*Roche has the exclusive right to launch and commercialize SRP-9001 outside the United States

\*\*\*\*Gene therapy and PPMO

Duchenne - Duchenne muscular dystrophy  
 EDMD - Emery Dreifuss muscular dystrophy  
 LGMD - Limb-girdle muscular dystrophy  
 MPS - Mucopolysaccharidosis IIIA  
 CMT - Charcot-Marie-Tooth disease  
 CNS - Central nervous system  
 CM - Cardiomyopathy  
 MS - Multiple Sclerosis

# Our Duchenne Muscular Dystrophy Pipeline

Information is current as of 10/1/2021, updates are made on a quarterly basis



\*Candidate received accelerated approval in the U.S., confirmatory studies required.

SRP-4051, SRP-4053 and SRP-4045 are not approved in Europe.

\*\*Other exon targets in development: 43, 44, 50, and 55

\*\*\*Roche has the exclusive right to launch and commercialize SRP-9001 outside the United States

\*\*\*\*Gene therapy and PPMO